425 related articles for article (PubMed ID: 16095766)
1. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
[TBL] [Abstract][Full Text] [Related]
2. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
7. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
[TBL] [Abstract][Full Text] [Related]
8. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.
Kotloff KL; Pasetti MF; Barry EM; Nataro JP; Wasserman SS; Sztein MB; Picking WD; Levine MM
J Infect Dis; 2004 Nov; 190(10):1745-54. PubMed ID: 15499528
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
Riddle MS; Kaminski RW; Williams C; Porter C; Baqar S; Kordis A; Gilliland T; Lapa J; Coughlin M; Soltis C; Jones E; Saunders J; Keiser PB; Ranallo RT; Gormley R; Nelson M; Turbyfill KR; Tribble D; Oaks EV
Vaccine; 2011 Sep; 29(40):7009-19. PubMed ID: 21787825
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
Chakraborty S; Harro C; DeNearing B; Bream J; Bauers N; Dally L; Flores J; Van de Verg L; Sack DA; Walker R
Clin Vaccine Immunol; 2016 Apr; 23(4):315-25. PubMed ID: 26865592
[TBL] [Abstract][Full Text] [Related]
11. Vaccine potential for inactivated shigellae.
Osorio M; Bray MD; Walker RI
Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
[TBL] [Abstract][Full Text] [Related]
13. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
Barry EM; Wang J; Wu T; Davis T; Levine MM
Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of WRSS1, a
Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
[No Abstract] [Full Text] [Related]
16. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
17. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
mSphere; 2018; 3(2):. PubMed ID: 29600284
[TBL] [Abstract][Full Text] [Related]
18. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
Rahman KM; Arifeen SE; Zaman K; Rahman M; Raqib R; Yunus M; Begum N; Islam MS; Sohel BM; Rahman M; Venkatesan M; Hale TL; Isenbarger DW; Sansonetti PJ; Black RE; Baqui AH
Vaccine; 2011 Feb; 29(6):1347-54. PubMed ID: 21040694
[TBL] [Abstract][Full Text] [Related]
19. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
